RespireRx Pharmaceuticals (RSPID) Stock Price, News & Analysis

Company Overview

RespireRx Pharmaceuticals Inc. engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. It has two drug platforms comprising ampakines, which are small molecule compounds to enhance the excitatory actions of the neurotransmitter glutamate at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complex; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is headquartered in Glen Rock, New Jersey.

Key Stats

• Today's Range: $0.0023 to $0.0023
• 50-Day Range: N/A
• 52-Week Range: $0.01 to $1.50
• Volume: 1.00 million shs
• Average Volume: 928,930 shs
• Market Capitalization: $166,223.30
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSPID Stock Analysis - Frequently Asked Questions

How have RSPID shares performed this year?

RespireRx Pharmaceuticals' stock was trading at $0.0008 at the beginning of the year. Since then, RSPID stock has increased by 187.5% and is now trading at $0.0023.
View the best growth stocks for 2025 here.

How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RSPID
• CIK: N/A
• Web: www.respirerx.com
• Phone: 201 444 4947
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 72,271,000
• Free Float: N/A
• Market Cap: $166,223.30
• Optionable: Not Optionable
• Beta: 0.15